This is a recording of a session from the AMP 2019 Annual Meeting & Expo. Purchase the entire AMP 2019 Annual Meeting & Expo Recordings for a significant discount!
As new targeted therapies for cancer become available, new genetic mechanisms of acquired resistance have emerged. This session discusses mechanisms of resistance to kinase inhibitors, anti-hormone therapy, PARP inhibitors, and other treatment modalities, the evolution of new strategies to overcoming resistance, and the current and anticipated value of molecular testing to aid therapy selection for patients with cancer.
Fei Dong, MD, Brigham and Women's Hospital, Boston, MA, US
Objectives:
- Describe genetic mechanisms of resistance to targeted therapies, including tyrosine kinase inhibitors, anti-hormone therapies, and PARP inhibitors.
- Interpret resistance mutations to guide patient care in the selection of second-line cancer therapies.
- Anticipate evolving challenges and needs in molecular testing with the emergenceof resistance to current and futuretargeted therapies.
Duration: 1.00 hr
Recording Date: November 8, 2019
CME/CMLE credit: 1.00 hr
Last day to purchase course and CE claim credit: December 24, 2022
